An injectable composite material containing bone morphogenetic protein-2 shortens the period of distraction osteogenesis in vivo. Academic Article uri icon

Overview

abstract

  • To investigate new methods that can decrease the duration of bone transport (BT) distraction osteogenesis, we injected composite materials containing recombinant human bone morphogenetic protein-2 (BMP-2) and induced the generation of a callus bridge by rapid segmental transport (4 mm/day) in a rabbit bone defect model. The composite materials consisted of BMP-2 (0, 30, or 100 µg), β-tricalcium phosphate powder (βTCP, 100 mg/animal; particle size, <100 µm), and polyethylene glycol (PEG; 40 mg/animal). A paste of equivalent composition was percutaneously injected at the lengthening and the docking sites after surgery and after BT, respectively. The radiographic, mechanical, and histological examinations 12 weeks post-operative revealed that the generation of bridging callus in the presence and in the absence of BMP-2 was significantly different. The callus mass in the bone defect region was adequately and consistently developed in the presence of 100 µg of BMP (administered for 6 weeks), and the bones were consolidated in 12 weeks. Such an adequate callus formation was not observed in the control animals without BMP-2 treatment. The result of this experimental study suggests the potential application of BMP-2 in accelerating callus formation and in enabling rapid bone transporting, thereby shortening the treatment period for the repair of diaphyseal bone defects by distraction osteogenesis.

publication date

  • September 29, 2010

Research

keywords

  • Biocompatible Materials
  • Bone Morphogenetic Protein 2
  • Bony Callus
  • Calcium Phosphates
  • Osteogenesis, Distraction
  • Tibial Fractures

Identity

Scopus Document Identifier

  • 79251579978

Digital Object Identifier (DOI)

  • 10.1002/jor.21225

PubMed ID

  • 20882597

Additional Document Info

volume

  • 29

issue

  • 3